【摘要】 目的探讨齐拉西酮与氟哌啶醇治疗精神分裂症的疗效和安全性。方法将94例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予齐拉西酮和氟哌啶醇治疗8周。分别于治疗前和治疗后2、4、6、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果治疗8周后,两组疗效近似(P>0.05),齐拉西酮组和氟哌啶醇组的有效率无显著性差异;齐拉西酮组的副反应发生率低于氟哌啶醇组,但无显著性差异。氟哌啶醇组锥体外系副反应明显高于齐拉西酮组(P<0.05)。结论齐拉西酮与氟哌啶醇对精神分裂症患者的疗效相当,副作用较小。更多还原

【Abstract】 Objective To study the efficacy and safety of Ziprasidone and Haloperidol in the treatment of Schizophrenia patients.Methods 94 patients with Schizophrenia by CCMD-3 were randomly allocated to two groups,treated respectively with Ziprasidone or Haloperidol for 8 weeks.The PANSS and TESS were employed to evaluate the efficacy and adverse effects respectively before and at the ends of 2,4,6,and 8 weeks treatment.Results The total effective rates for the Ziprasidone and Haloperidol groups were similar after the 8-week treatment.There was no significant difference between the two groups.Incidence of adverse effects in the Ziprasidone group was lower than that in the Haloperidol group,but the difference was not significant.The rates of extrapyramidal symptoms were significantly higher in the Haloperidol group than those in the Ziprasidone group(P<0.05).Conclusion Ziprasidone has similar efficacy as Haloperidol but fewer side effects in the treatment of Schizophrenia patients.更多还原